Published in J Clin Gastroenterol on December 01, 2000
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
The medical management of primary sclerosing cholangitis. Medscape J Med (2008) 0.79
Indications for non-transplant surgery in primary sclerosing cholangitis. HPB (Oxford) (2005) 0.76
Primary sclerosing cholangitis: emerging new promising therapies. J Clin Gastroenterol (2000) 0.75
Management Of Primary Sclerosing Cholangitis. Gastroenterol Hepatol (N Y) (2006) 0.75
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A (2001) 3.07
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Mutation of the mouse hepatocyte nuclear factor/forkhead homologue 4 gene results in an absence of cilia and random left-right asymmetry. J Clin Invest (1998) 2.48
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) (1992) 1.96
Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol (2001) 1.93
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther (2012) 1.69
2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol (1992) 1.65
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med (2001) 1.65
Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol (1998) 1.58
LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol (2000) 1.54
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
Enzyme replacement therapy for Gaucher disease. Blood (1991) 1.48
Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia. Am J Clin Pathol (1994) 1.45
Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol (1998) 1.42
Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia. Mayo Clin Proc (1996) 1.38
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2010) 1.31
Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood (1993) 1.29
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology (1997) 1.25
Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat (1996) 1.21
Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol (1986) 1.19
Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 1.17
Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol (2000) 1.14
A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer (2001) 1.13
Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model. Ann Intern Med (1993) 1.13
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther (2011) 1.12
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology (1986) 1.11
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer (2001) 1.10
Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther (2014) 1.08
Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology. Gastroenterology (1985) 1.08
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver (2001) 1.05
Cutaneous metastases as a manifestation of internal carcinoma: diagnostic and prognostic significance. Am Surg (1972) 1.05
Tendinopathy and tears of the rotator cuff are associated with hypoxia and apoptosis. J Bone Joint Surg Br (2010) 1.05
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl (2001) 1.05
Influenza infection in patients before and after liver transplantation. Liver Transpl (2000) 1.02
Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat (2011) 1.01
Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood (1993) 1.01
Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood (1994) 1.00
Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest (1995) 1.00
RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone (2010) 0.99
Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther (2009) 0.97
Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther (2009) 0.97
Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest (2001) 0.97
Frequency of association of mammary tumor glycoprotein antigen and other markers with human breast tumors. Cancer Res (1979) 0.96
The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res (1990) 0.96
Misuse of marrow examination in the diagnosis of Gaucher disease. Blood (1990) 0.96
The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther (2004) 0.94
Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology (1999) 0.94
Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol (2006) 0.93
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl (2001) 0.92
Transjugular intrahepatic portosystemic shunts (TIPS): a decade later. J Clin Gastroenterol (2000) 0.92
Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat (2011) 0.91
Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage. Proc Natl Acad Sci U S A (1990) 0.91
Splenectomy for hairy cell leukemia in pregnancy. J Perinatol (1998) 0.90
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat (2013) 0.90
Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther (2008) 0.90
Idiopathic fatty liver of pregnancy: findings in ten cases. Medicine (Baltimore) (1984) 0.88
Ocular reticulum cell sarcoma. Presentation as retinal detachment with demonstration of monoclonal immunoglobulin light chains on the vitreous cells. Arch Ophthalmol (1981) 0.88
Patent ductus venosus in an adult presenting as pulmonary hypertension, right-sided heart failure, and portosystemic encephalopathy. Am J Med (2001) 0.87
Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med (2000) 0.87
Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol (1997) 0.86
Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial. J Clin Gastroenterol (2001) 0.84
Iron overload after prolonged intramuscular iron therapy. N Engl J Med (1989) 0.84
Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. J Viral Hepat (2010) 0.84
Natural progression of untreated hepatolithiasis. J Clin Gastroenterol (2001) 0.84
Percutaneous retrieval of a large Palmaz stent from the pulmonary artery. J Vasc Interv Radiol (1994) 0.84
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther (2014) 0.84
Health-related quality of life (HRQL) in chronic liver disease. Dig Liver Dis (2005) 0.84
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia (2003) 0.83
Morbidity trends in the medical wards at Groote Schuur Hospital--1971 and 1982. S Afr Med J (1985) 0.83
Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. Am J Pathol (1998) 0.83
Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J Clin Gastroenterol (2001) 0.83
Acute fatty liver of pregnancy. Dig Dis Sci (1985) 0.83
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis (2015) 0.82
Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after liver transplantation. Hepatology (1993) 0.82
Survival and resource utilization in liver transplant recipients: the impact of admission to the intensive care unit. Transplant Proc (2003) 0.82
Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma (1999) 0.81
2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol (1991) 0.81
The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med (2000) 0.81
The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med (2006) 0.81
Dilutional acidosis. South Med J (1990) 0.81
Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT. Exp Mol Pathol (2013) 0.80
Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. Clin Exp Rheumatol (2004) 0.80
Multiple primary cancers: relative risk in New Mexico's triethnic population. Cancer (1977) 0.80
Toxic megacolon complicating Campylobacter enterocolitis. J Clin Gastroenterol (1986) 0.79
2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med (1993) 0.79
Chronic liver disease and health-related quality of life. Gastroenterology (2001) 0.78
Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat (2011) 0.78
Purine metabolism of lymphocytes. Targets for chemotherapy drug development. Hematol Oncol Clin North Am (1994) 0.78
Mortality associated with alcohol-related liver disease. Aliment Pharmacol Ther (2013) 0.78
Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations. Am J Gastroenterol (2001) 0.78